Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity Of Co’s Gamma Secretase Inhibitor AL101 In Desmoid Tumors
Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced
Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101
Ayala Pharmaceuticals Inc (NASDAQ:AYLA) announced new preliminary data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101…
38 Stocks Moving In Thursday’s Mid-Day Session
Gainers
IronNet Cybersecurity, Inc. (NASDAQ: IRNT) shares jumped 30.4% to $41.90 amid increased retail investor interest in the stock on social media.
Oppenheimer Maintains Outperform on Ayala Pharmaceuticals, Lowers Price Target to $25
Oppenheimer analyst Jay Olson maintains Ayala Pharmaceuticals (NASDAQ:AYLA) with a Outperform and lowers the price target from $27 to $25.
Recap: Ayala Pharmaceuticals Q2 Earnings
Shares of Ayala Pharmaceuticals (NASDAQ:AYLA) were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share were down 1.35% over the past year to ($0.75), which missed the estimate of ($0.63).
Ayala Pharmaceuticals Q2 EPS $(0.75) Down From $(0.74) YoY
Ayala Pharmaceuticals (NASDAQ:AYLA) reported quarterly losses of $(0.75) per share. This is a 1.35 percent decrease over losses of $(0.74) per share from the same period last year.
The Daily Biotech Pulse: Lilly, Morphic’s Positive Data At ECCO, Humanigen’s COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 8)
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 158 companies reached new 52-week lows.